These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
722 related items for PubMed ID: 18400579
1. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene. Lee WL, Cheng MH, Chao HT, Wang PH. Taiwan J Obstet Gynecol; 2008 Mar; 47(1):24-31. PubMed ID: 18400579 [Abstract] [Full Text] [Related]
2. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. Lee WL, Chao HT, Cheng MH, Wang PH. Maturitas; 2008 Jun 20; 60(2):92-107. PubMed ID: 18534794 [Abstract] [Full Text] [Related]
3. Tamoxifen, raloxifene and the prevention of breast cancer. Bentrem DJ, Craig Jordan V. Minerva Endocrinol; 2002 Jun 20; 27(2):127-39. PubMed ID: 11961504 [Abstract] [Full Text] [Related]
4. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer. Ganz PA, Land SR. Menopause; 2008 Jun 20; 15(4 Suppl):797-803. PubMed ID: 18596601 [Abstract] [Full Text] [Related]
11. Prevention of hormone-related cancers: breast cancer. Dunn BK, Wickerham DL, Ford LG. J Clin Oncol; 2005 Jan 10; 23(2):357-67. PubMed ID: 15637398 [Abstract] [Full Text] [Related]
12. Raloxifene (Evista) for breast cancer prevention in postmenopausal women. Med Lett Drugs Ther; 2006 May 08; 48(1234):37. PubMed ID: 16685245 [Abstract] [Full Text] [Related]
13. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. Jordan VC, O'Malley BW. J Clin Oncol; 2007 Dec 20; 25(36):5815-24. PubMed ID: 17893378 [Abstract] [Full Text] [Related]
15. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. Pinkerton JV, Goldstein SR. Menopause; 2010 Dec 20; 17(3):642-53. PubMed ID: 20107426 [Abstract] [Full Text] [Related]
16. Recent results from clinical trials using SERMs to reduce the risk of breast cancer. Vogel VG. Ann N Y Acad Sci; 2006 Nov 20; 1089():127-42. PubMed ID: 17261762 [Abstract] [Full Text] [Related]
17. Selective estrogen receptor modulators and postmenopausal health. Roe EB, Chiu KM, Arnaud CD. Adv Intern Med; 2000 Nov 20; 45():259-78. PubMed ID: 10635051 [Abstract] [Full Text] [Related]
19. [Chemoprevention of breast cancer. Clinical trials in pharmacological prevention]. Ricart JJ. Medicina (B Aires); 2004 Nov 20; 64(1):66-72. PubMed ID: 15034961 [Abstract] [Full Text] [Related]
20. Hormonal interventions to prevent hormonal cancers: breast and prostate cancers. Dunn BK, Ford LG. Eur J Cancer Prev; 2007 Jun 20; 16(3):232-42. PubMed ID: 17415094 [Abstract] [Full Text] [Related] Page: [Next] [New Search]